

Phase I study of S 78454 in combination with radiotherapy in patients with solid tumour

Submission date 08/07/2013	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/08/2013	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 22/02/2019	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

Contact information

Type(s)

Scientific

Contact name

Dr Eric Deutsch

Contact details

Institut de Cancérologie Gustave Roussy
39 rue Camille Desmoulins
Villejuif
France
94 805

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

CL1-78454-004

Study information

Scientific Title

Phase I dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) inhibitor S 78454 in combination with standard hypofractionated radiotherapy in patients with advanced solid tumour

Study objectives

To establish the safety profile and the recommended Phase II dose of S 78454 in combination with radiotherapy

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval was obtained before recruitment of the first participants

Study design

International multicentric non-randomised open-label dose escalation Phase I study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Solid tumours

Interventions

Capsules containing 20 mg of S 78454 administered orally. Treatment duration is at the discretion of the investigator.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

Abexinostat (S 78454)

Primary outcome measure

Dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) at the end of cycle measured by adverse events monitoring

Secondary outcome measures

1. Safety profile at each visit measured by adverse events monitoring
2. Tumour response evaluation at baseline and at the final visit measured by imaging and blood tests
3. Tumour perfusion measurements only for schedule 1 using functional imaging
4. Exploration of changes in biological markers (optional part in schedule 1) using biopsies

Overall study start date

02/09/2010

Completion date

07/08/2015

Eligibility

Key inclusion criteria

1. Solid tumour, with measurable or evaluable disease, requiring a course of hypofractionated radiotherapy
2. Ability to swallow oral capsule(s) without difficulty
3. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
4. Estimated life expectancy of more than 20 weeks
5. Adequate haematological, renal and hepatic functions

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

90

Key exclusion criteria

1. Allogenic bone marrow transplant
2. Major surgery within previous 4 weeks
3. Chemotherapy within previous 3 weeks (6 weeks in case of nitrosoureas)
4. Previous radiotherapy on the same area
5. Cumulative radiation therapy involving more than 25% of the total bone marrow
6. Immunotherapy or hormone therapy within previous 2 weeks, except stable luteinizing hormone-releasing hormone (LHRH) agonist therapy for prostate cancer, stable oral glucocorticoid and mineralocorticoid replacement for adrenal insufficiency, stable mitotane for adrenal carcinoma, or oral contraceptives
7. Concurrent therapeutic anticoagulation by Vitamin K antagonists
8. Patients treated by valproic acid

9. Risk factors for, or use of medications known to prolong QTc interval and that may be associated with Torsades de Pointes.

Date of first enrolment

02/09/2010

Date of final enrolment

04/02/2015

Locations

Countries of recruitment

France

Italy

Study participating centre

Institut de Cancérologie Gustave Roussy

Villejuif

France

94 805

Sponsor information

Organisation

Pharmacyclics LLC (USA)

Sponsor details

999 East Arques Avenue

Sunnyvale

United States of America

94085

Sponsor type

Industry

Website

www.pharmacyclics.com

ROR

<https://ror.org/03hm8w204>

Funder(s)

Funder type

Industry

Funder Name

Pharmacyclics LLC (USA)

Results and Publications

Publication and dissemination plan

The CSR will be written by Pharmacyclics in 2016

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	24/12/2016		Yes	No